Metraipolis › archive › dc_d6cf2b4dc606

Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41278271
DOI
10.3389/fonc.2025.1624286
License (as archived)
solo-consultazione
Archived
2026-11-08T18:35:34.257Z
SHA-256 of the archived text
c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2
Stable URL of this page
https://metraipolis.com/documento/dc_d6cf2b4dc606

How to cite

Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271 — Europe PMC (en), https://europepmc.org/article/MED/41278271 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d6cf2b4dc606 (Metraipolis archive dc_d6cf2b4dc606, sha256 c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2)
BibTeX
@misc{dcd6cf2b4dc606,
  title = {Efficacy and safety of apatinib or anlotinib combined with PD-1 inhibitors-based therapy as subsequent-line treatment for recurrent or metastatic… — Europe PMC PMID:41278271},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41278271},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d6cf2b4dc606; sha256 c9ba09a32580e709492180a7cbf165819196b45d3c32d9bd9b0c73b7be06e1c2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41278271. Agents can read the archived copy with the MCP tool read_document.